FCGR2B and autoimmune disease: FcγRIIb expression can impair immunotherapy efficacy in vivo by suppressing activating FcγR signalling [11, 12] whilst the FCGR2B-232I/T SNP in the transmembrane domain of FcγRIIb impairs its inhibitory function and has been implicated in predisposition to autoimmune disease [3].